Tuesday saw a somber close for the Dow Jones index, trailing by more than 60 points. Insider dealings, representing either confidence or apprehension in a company’s future, are regarded as vital indicators for investors and traders delving into the unpredictable world of penny stocks.

Here’s a close look at a few recent significant insider transactions across some penny stocks. For more details, explore Benzinga’s insider transactions platform.

Retractable Technologies

• The Deal: Retractable Technologies, Inc. RVP President and CEO Thomas J Shaw
  acquired a total of 21,687 shares at an average price of $1.28. The acquisition
  amounted to approximately $27,768.
• Recent Development: On Nov. 14, Retractable Technologies reported an $8.7
  million loss from operations for the first nine months of 2023.
• Company Profile: Retractable Technologies Inc specializes in designing,
  developing, manufacturing, and marketing safety syringes and other safety medical products for
  the healthcare industry.

Citizens

• The Deal: Citizens, Inc. CIA President and CEO Gerald Shields acquired a
  total of 29,182 shares at an average price of $3.00. The transaction involved about
  $87,546.
• Recent Development: The company noted an increase in total revenues to $59.4
  million in the third quarter from $56.2 million in the same period last year.
• Company Profile: Citizens Inc is an insurance holding company catering to
  the life insurance needs of individuals in the United States.

Beasley Broadcast Group

• The Deal: Beasley Broadcast Group, Inc. BBGI Chief Operating Officer Brian E Beasley
  acquired a total of 1,200 shares at an average price of $0.85. The insider spent
  around $1,020 for the purchase.
• Recent Development: Beasley Broadcast recorded underwhelming fourth-quarter
  sales.
• Company Profile: Beasley Broadcast Group Inc is a multi-platform media
  company, primarily engaged in operating radio stations across the United States.

Rezolute

• The Deal: Rezolute, Inc. RZLT CFO Daron Evans acquired a total of 50,900 shares
  at an average price of $1.35. The insider invested roughly $66,741 in purchasing these
  shares.
• Recent Development: Rezolute posted a narrower-than-expected quarterly loss.
• Company Profile: Rezolute Inc is a biopharmaceutical company that develops
  innovative, sustained-release injectable therapies.

Don’t forget to check out our premarket coverage here